Expression and effect of inhibition of the ubiquitin-conjugating enzyme E2C on esophageal adenocarcinoma.

Ubiquitin-dependent proteolysis of cyclins plays a critical role in cell cycle progression and tumorigenesis. We examined the expression of ubiquitin-conjugating enzyme E2C (UBE2C) during progression from Barrett's metaplasia to esophageal adenocarcinoma (EA) and the effects of targeting this enzyme on EA-derived cell lines. Using oligonucleotide microarrays UBE2C expression was elevated in 73% (11 of 15) of EAs relative to Barrett's metaplasia. Tissue microarray showed elevated UBE2C in 70% (7 of 10) of dysplastic samples and in 87% (58 of 67) of tumors relative to metaplastic samples. Transfection of dominant-negative UBE2C into Seg-1 cells decreased proliferation (P = .04) and increased mitotic arrest compared to vector controls (63.5% vs 6.8%; P < .001). Transfection of UBE2C small interfering RNA also caused inhibiton of cell proliferation and distortion of the cell cycle, with maximal increase of G(2) cells (155% of mock cells) at 72 hours and of S-phase cells (308% of mock cells) at 24 hours. Treatment of Seg-1 cells with the proteasome inhibitor MG-262 (1 nM-1 microM) showed decreased proliferation (P = .02). EA-derived cells expressing UBE2C are sensitive to treatment with MG-262 and to silencing of UBE2C, suggesting that patients with EAs overexpressing UBE2C may benefit from agents targeting this ubiquitin-conjugating enzyme.

[1]  Yasuo Takahashi,et al.  Detection of aberrations of ubiquitin-conjugating enzyme E2C gene (UBE2C) in advanced colon cancer with liver metastases by DNA microarray and two-color FISH. , 2006, Cancer genetics and cytogenetics.

[2]  Marc W. Kirschner,et al.  Autonomous regulation of the anaphase-promoting complex couples mitosis to S-phase entry , 2004, Nature.

[3]  Francesco Hofmann,et al.  Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin , 2004, Oncogene.

[4]  T. Vaughan,et al.  Determinants of survival following the diagnosis of esophageal adenocarcinoma (United States) , 1996, Cancer Causes & Control.

[5]  B. Mezquita,et al.  Down‐regulation of Flt‐1 gene expression by the proteasome inhibitor MG262 , 2003, Journal of cellular biochemistry.

[6]  K. Lindsten,et al.  A transgenic mouse model of the ubiquitin/proteasome system , 2003, Nature Biotechnology.

[7]  Akira Nakagawara,et al.  UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. , 2003, Cancer research.

[8]  Tim Hunt,et al.  Unmasking the S-Phase-Promoting Potential of Cyclin B1 , 2003, Science.

[9]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[10]  Amir Jazaeri,et al.  Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. , 2003, Cancer research.

[11]  A. Terman,et al.  Proteasome Inhibition Enhances Lipofuscin Formation , 2002, Annals of the New York Academy of Sciences.

[12]  W. C. Hwang,et al.  Structural and Functional Analysis of the Human Mitotic-specific Ubiquitin-conjugating Enzyme, UbcH10* , 2002, The Journal of Biological Chemistry.

[13]  Y. Kanai,et al.  Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. , 2002, Molecular pharmacology.

[14]  L. Cooley,et al.  Control of DNA Replication and Chromosome Ploidy by Geminin and Cyclin A , 2002, Molecular and Cellular Biology.

[15]  M. Tilby,et al.  Decreased telomerase activity is not a reliable indicator of chemosensitivity in testicular cancer cell lines. , 2002, European journal of cancer.

[16]  P. Sancho,et al.  Effect of Glutathione Depletion on Antitumor Drug Toxicity (Apoptosis and Necrosis) in U-937 Human Promonocytic Cells , 2001, The Journal of Biological Chemistry.

[17]  M. Kitagawa,et al.  Cell cycle-dependent expression of mammalian E2-C regulated by the anaphase-promoting complex/cyclosome. , 2000, Molecular biology of the cell.

[18]  C. V. D. van de Velde,et al.  Effect of glutathione depletion on inhibition of cell cycle progression and induction of apoptosis by melphalan (L-phenylalanine mustard) in human colorectal cancer cells. , 1999, Biochemical pharmacology.

[19]  J. Fraumeni,et al.  Changing patterns in the incidence of esophageal and gastric carcinoma in the United States , 1998, Cancer.

[20]  S. Welford,et al.  EWS/FLI1 up regulates mE2-C, a cyclin-selective ubiquitin conjugating enzyme involved in cyclin B destruction , 1998, Oncogene.

[21]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[22]  F. Townsley,et al.  Proteolytic ratchets that control progression through mitosis. , 1998, Trends in cell biology.

[23]  D. Beer,et al.  Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. , 1997, Cancer research.

[24]  W. Baumeister,et al.  Active Site-directed Inhibitors of Rhodococcus 20 S Proteasome , 1997, The Journal of Biological Chemistry.

[25]  A. Hershko,et al.  Dominant-negative cyclin-selective ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[26]  S. J. Darnton,et al.  Five newly established oesophageal carcinoma cell lines: phenotypic and immunological characterization. , 1997, British Journal of Cancer.

[27]  Marc W. Kirschner,et al.  How Proteolysis Drives the Cell Cycle , 1996, Science.

[28]  Aaron Ciechanover,et al.  The ubiquitin-proteasome proteolytic pathway , 1994, Cell.

[29]  U. Strausfeld,et al.  Cyclin a is required for the onset of DNA replication in mammalian fibroblasts , 1991, Cell.

[30]  T. Hunter,et al.  Cyclins and cancer , 1991, Cell.

[31]  C. Harris,et al.  Establishment and characterization of SV40 T-antigen immortalized human esophageal epithelial cells. , 1991, Cancer research.

[32]  Ralph G. Pearson,et al.  Kinetics and mechanism , 1961 .